IceCure Highlights Expanding Commercial Adoption of ProSense™ Cryoablation in Brazil Following FDA Clearance for Breast Cancer

About this update from Icecure Medical Ltd.

Growing physician interest and commercial adoption for ProSense™ in Brazil's expanding interventional oncology markets increased following FDA authorization Independent study evaluating breast cancer cryoablation in 750 patients across Brazil, led by renowned breast surgeon Dr. Vanessa Sanvido, is underway Dr. Toulsie Ramtohul of Institut Curie, a ProSense™ user set to lead a 900-patient breast cancer cryoablation study in France, invited to key Brazilian hospitals and interventional oncology conference to share clinical expertise CAESAREA, Israel, July 6, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today highlighted the growing international interest in its ProSense™ system in Brazil at the Simpósio de Radiologia Intervencionista em Oncologia ("SOBRICE Onco 2026"), one of the country's leading interventional oncology congresses. "IceCure's ProSense™ holds Agência Nacional de Vigilância Sanitária ("ANVISA") regulatory approval in Brazil and is experiencing growing commercial expansion in the country. We believe the recent U.S. Food and Drug Administration's ("FDA") marketing authorization for early-stage, low-risk breast cancer has provided significant tailwind, boosting awareness and interest among Brazilian physicians and institutions", commented IceCure CEO, Eyal Shamir "Commercial procedures are already being performed, including for breast, lung, kidney cancer and musculoskeletal tumors", Shamir continued. Leading experts in cryoablation such as Dr. José Hugo Luz, a member of the SOBRICE Board of Directors and Chief of Interventional Radiology at the Instituto Nacional De Câncer, Dr. Vanessa Sanvido, a breast surgeon at HCor Hospital in São Paulo, and others are among those advocating for the adoption of ProSense® in key medical centers throughout the country. At SOBRICE Onco 2026, renowned experts in breast cryoablation, including breast surgeon Dr. Vanessa Sanvido of the HCor Hospital in São Paulo, Brazil and interventional radiologist Dr. Toulsie Ramtohul of the Institut Curie in Paris, France were invited to attend the breast cancer session to present their clinical experience and results with ProSense™ to the Brazilian oncology ...

View stock analysis, news, and events for Icecure Medical Ltd.